Abstract
Chronic low-grade subclinical inflammation has been increasingly recognized as an interposer in the endocrine, metabolic and reproductive disturbances that characterize the polycystic ovary syndrome (PCOS). Abdominal adiposity and obesity are often present in PCOS. Mounting evidence indicates that adipose tissue is involved in innate and adaptive immune responses. Continuous release of inflammatory mediators such as cytokines, acute phase proteins, and adipokines perpetuates the inflammatory condition associated with obesity in women with PCOS, possibly contributing to insulin resistance and other long-term cardiometabolic risk factors. Genetic variants in the genes encoding inflammation-related mediators underlie the development of PCOS and their interaction with environmental factors may contribute to the heterogeneous clinical phenotype of this syndrome. In the future, strategies ameliorating inflammation may prove useful for the management of PCOS and associated conditions.
Keywords: Polycystic ovary syndrome, androgen excess, hyperandrogenism, inflammation, endothelial dysfunction, insulin resistance, abdominal adiposity, obesity.
Current Pharmaceutical Design
Title:Mediators of Low-Grade Chronic Inflammation in Polycystic Ovary Syndrome (PCOS)
Volume: 19 Issue: 32
Author(s): Miriam Ojeda-Ojeda, Mora Murri, Maria Insenser and Hector F. Escobar-Morreale
Affiliation:
Keywords: Polycystic ovary syndrome, androgen excess, hyperandrogenism, inflammation, endothelial dysfunction, insulin resistance, abdominal adiposity, obesity.
Abstract: Chronic low-grade subclinical inflammation has been increasingly recognized as an interposer in the endocrine, metabolic and reproductive disturbances that characterize the polycystic ovary syndrome (PCOS). Abdominal adiposity and obesity are often present in PCOS. Mounting evidence indicates that adipose tissue is involved in innate and adaptive immune responses. Continuous release of inflammatory mediators such as cytokines, acute phase proteins, and adipokines perpetuates the inflammatory condition associated with obesity in women with PCOS, possibly contributing to insulin resistance and other long-term cardiometabolic risk factors. Genetic variants in the genes encoding inflammation-related mediators underlie the development of PCOS and their interaction with environmental factors may contribute to the heterogeneous clinical phenotype of this syndrome. In the future, strategies ameliorating inflammation may prove useful for the management of PCOS and associated conditions.
Export Options
About this article
Cite this article as:
Ojeda-Ojeda Miriam, Murri Mora, Insenser Maria and Escobar-Morreale F. Hector, Mediators of Low-Grade Chronic Inflammation in Polycystic Ovary Syndrome (PCOS), Current Pharmaceutical Design 2013; 19 (32) . https://dx.doi.org/10.2174/1381612811319320012
DOI https://dx.doi.org/10.2174/1381612811319320012 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Alcohol Drinking, Apolipoprotein Polymorphisms and the Risk of Cardiovascular Diseases
Current Neurovascular Research Signs and Related Mechanisms of Ethanol Hepatotoxicity
Current Drug Abuse Reviews Molecular Imaging of Vascular Inflammation
Current Pharmaceutical Design Dynamics of Diabetes and Obesity: An Alarming Situation in the Developing Countries in Asia
Mini-Reviews in Medicinal Chemistry Aortic Dissection: A Review of the Pathophysiology, Management and Prospective Advances
Current Cardiology Reviews Treating Hypertension in the Elderly: Common Problems and Solutions
Current Hypertension Reviews Oleic Acid in Olive Oil: From a Metabolic Framework Toward a Clinical Perspective
Current Pharmaceutical Design Ethnicity and Drug Therapy for Hypertension
Current Pharmaceutical Design Anesthesia and Postoperative Cognitive Dysfunction (POCD)
Central Nervous System Agents in Medicinal Chemistry Actions of Rho-Kinase Inhibitors in Cardiovascular Diseases
Current Enzyme Inhibition Novel 4-Oxothienopyrimidinyl Propanoic Acid Derivatives as AMPActivated Protein Kinase (AMPK) Activators
Letters in Drug Design & Discovery Joint Effect of ABCA7 rs4147929 and Body Mass Index on Progression from Mild Cognitive Impairment to Alzheimer’s Disease: The Shanghai Aging Study
Current Alzheimer Research Postoperative Atrial Fibrillation - What Do We Really Know?
Current Vascular Pharmacology Palliative Combined Percutaneous Balloon Aortic Valvuloplasty and Unprotected Left Main Stenting in End Stage Renal Disease
Current Cardiology Reviews Antihyperlipidemic and Antiobesity Potential of <i>Aquilaria agallocha</i> and <i>Borago officinalis</i> in Fixed-Dose Combination; A Contingent Probe with Atorvastatin and Orlistat
Current Bioactive Compounds A Novel Natural Polymers Based Nanoparticles Gel Formulation for the Treatment of Rheumatoid Arthritis: Optimization and <i>In-vivo</i> Evaluation
Drug Delivery Letters Muscarinic Acetylcholine Receptor-Interacting Proteins (mAChRIPs): Targeting the Receptorsome
Current Drug Targets Bortezomib – First Therapeutic Proteasome Inhibitor for Cancer Therapy: A Review of Patent Literature
Recent Patents on Anti-Cancer Drug Discovery Polydeoxyribonucleotide (PDRN): A Safe Approach to Induce Therapeutic Angiogenesis in Peripheral Artery Occlusive Disease and in Diabetic Foot Ulcers
Cardiovascular & Hematological Agents in Medicinal Chemistry Senescence and Cell Death Pathways and Their Role in Cancer Therapeutic Outcome
Current Medicinal Chemistry